SCHEMBL317227

SCHEMBL317227

CCN(CC)C(=O)c1cc(CCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)cc(CCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 4/20 0.42
LMNA P02545 3/20 0.41
RECQL P46063 1/20 0.41
HPGD P15428 5/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
HSP90AA1 P07900 5/20 0.36
HSP90AB1 P08238 5/20 0.36
PDK2 Q15119 1/20 0.36
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
ALDH1A1 P00352 2/20 0.34
MAPT P10636 1/20 0.34
OPRM1 P35372 1/20 0.34
OPRD1 P41143 1/20 0.34
OPRK1 P41145 1/20 0.34
PPARG P37231 1/20 0.33
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL316846 0.86 MLYCD (0.52) MLYCDLMNAHPGDSMN1; SMN2MEN1
SCHEMBL317228 0.74 MLYCD (0.46) MLYCDLMNARECQLHPGDSMN1; SMN2
SCHEMBL317439 0.74 MLYCD (0.43) MLYCDLMNARECQLHPGDSMN1; SMN2
SCHEMBL317438 0.69 MLYCD (0.41) MLYCDLMNARECQLHPGDSMN1; SMN2
SCHEMBL316847 0.69 MLYCD (0.58) MLYCDLMNAHPGDSMN1; SMN2MEN1
SCHEMBL25513759 0.69 CA12 (0.36) LMNAMEN1KMT2APDK2ALDH1A1
SCHEMBL25513750 0.69 CA12 (0.36) LMNAMEN1KMT2APDK2ALDH1A1
SCHEMBL316508 0.69 MLYCD (0.54) MLYCDLMNAHPGDSMN1; SMN2MEN1
SCHEMBL10615014 0.68 LMNA (0.45) MLYCDLMNA
SCHEMBL26575340 0.68 HDAC1 (0.36) LMNASMN1; SMN2MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093429-B2 Fluoroamine having perfluoroalkyl group, process for producing the same, method of fluorination therewith, and method of recovering amide having perfluoroalkyl group NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) 2012-01-10 US disclosed
US-20090198086-A1 FLUOROAMINE HAVING PERFLUOROALKYL GROUP, PROCESS FOR PRODUCING THE SAME, METHOD OF FLUORINATION THEREWITH, AND METHOD OF RECOVERING AMIDE HAVING PERFLUOROALKYL GROUP NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) 2009-08-06 US disclosed
EP-2022776-A1 FLUOROAMINE HAVING PERFLUOROALKYL GROUP, PROCESS FOR PRODUCING THE SAME, METHOD OF FLUORINATION THEREWITH, AND METHOD OF RECOVERING AMIDE HAVING PERFLUOROALKYL GROUP National University Corporation Hokkaido University (JP) 2009-02-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090198086-A1 FLUOROAMINE HAVING PERFLUOROALKYL GROUP, PROCESS FOR PRODUCING THE SAME, METHOD OF FLUORINATION THEREWITH, AND METHOD OF RECOVERING AMIDE HAVING PERFLUOROALKYL GROUP AFF2, AFF1, PFAS MLYCD 2497/4885LMNA 3620/4885RECQL 511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.